Health Condition 1: null- Acute Adenolymphangitis (ADL) due to Lymphatic Filariasis.
Conditions
Interventions
Intervention1: Predefined Homoeopathic medicines and standard allopathic treatment: Homoeopathic medicines shall be the intervention to be studied and allopathic medicines shall be the standard compar
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: ? Patients falling in under the predefined group of medicines. ? The patient with the presence of local signs and symptoms of acute ADL such as pain, tenderness, erythema, red streaks, retrograde lymphangitis local swelling and warmth in the groin, with or without associated constitutional symptoms such as fever, nausea and vomiting reporting within 72 hours of attack either with previous history of ADL attacks or reporting for the first time from the endemic areas shall be enrolled in the study. In known cases of LF, having acute ADL, only the cases with Grade 1 and 2 lymphoedema shall be included in the study population.
Exclusion criteria
Exclusion criteria: ? Acute attacks of ADL in known cases of Lymphatic filariasis with Grade III and IV lymphoedema and chronic hydrocele cases. ? The cases of lymphangitis due to the following conditions are to be excluded - o Thrombophlebitis o Infection (ascending lymphangitis) o Trauma ? Patients suffering from diabetes mellitus, severe systemic illness, congestive cardiac failure, nephrotic syndrome, malignancy and congenital lymphatic system abnormality. ? Patients coming after taking any treatment for the present ADL attack will be excluded. ? Patients deemed unfit by the investigator for participation in the study. ? Patient not willing to sign the written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement in Acute ADL attack as evident from the ADL scoring scale. Timepoint: Daily follow up will be done for each Acute ADL attack for 11 days. ? After the acute phase subsides, the patient will be followed up weekly/ fortnightly/ monthly till 6 months from the date of enrollment as per the requirement. | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease in frequency, duration and intensity of subsequent attacks, if any. WHOQOL-BREF, quality of life scale.Timepoint: Decrease in frequency, duration and intensity of subsequent attacks, if any, to be reviewed at monthly interval. WHOQOL-BREF, quality of life scale shall be used to assess the quality of life of patients at entry, on 11th day of follow up and at the end of 6months. It will also be repeated in case the ADL recurs. | — |
Countries
India
Contacts
Public ContactDr Lipi Pushpa
Central Council for Research in Homoeopathy
Outcome results
None listed